The best rules for antimicrobial stewardship in urogenital tract infections.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
4
9
2020
medline:
13
4
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
Urinary tract infections (UTIs) belong to the most common community-acquired and nosocomial infections, but therapy of UTIs is limited by resistance of pathogens and nonoptimal using of antibacterials. Narrative review of recent (2020-2018) literature dedicated to antimicrobial stewardship (AMS) in urological infections has been done. Analysis of recent 64 articles has shown following principles of AMS for UTIs: selecting the correct drug, correct dose, and shortest clinically effective duration of therapy whenever possible, is a base for optimal antimicrobial stewardship; symptomatic UTIs should be treated with antimicrobials to alleviate symptoms, and in the case of more serious infection, to prevent complications; in both symptomatic and asymptomatic infection, quantitative culture is the gold standard for diagnosis; we have to avoid prescriptions of antibiotics when possible; we have to follow European and National Guidelines; we must avoid prescription of fluoroquinolones as empiric therapy for UTIs by many reasons, one of these is urogenital tuberculosis; the choice of antibiotic for UTI should be based on local level of resistance of uropathogens. Studies of antimicrobial stewardship in urology are limited. Nevertheless, there are some golden rules, which may help to reduce inappropriate use of antimicrobials, improve patient outcomes, reduce side effects of antibiotic therapy, decrease the emergence and spread of multidrug-resistant infections, as well as decrease total costs of the therapy.
Identifiants
pubmed: 32881727
doi: 10.1097/MOU.0000000000000817
pii: 00042307-202011000-00012
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
838-844Références
Kot B. Antibiotic resistance among uropathogenic Escherichia coli. Pol J Microbiol 2019; 68:403–415.
Horie A, Nariai A, Katou F, et al. Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole. Clin Exp Nephrol 2019; 23:1306–1314.
Harding C, Rantell A, Cardozo L, et al. How can we improve investigation, prevention and treatment for recurrent urinary tract infections - ICI-RS. Neurourol Urodyn 2019; 38: (Suppl 5): S90–S97.
Thänert R, Reske KA, Hink T, et al. Comparative genomics of antibiotic-resistant uropathogens implicates three routes for recurrence of urinary tract infections. mBio 2019; 10:e01977–e02019.
Palagin IS, Sukhorukova MV, Dehnich AV. and the DARMIS-2018 research group. Antibiotic resistance of causative agents of community-acquired urinary tract infections in Russia: results of a multicenter study ‘DARMIS-2018’. KMAX 2019; 21:134–146.
Wagenlehner F, Tandogdu Z, Bartoletti R, et al. The global prevalence of infections in urology study: a long-term, worldwide surveillance study on urological infections. Pathogens 2016; 5:1–8.
Grabe MJ, Resman F. Antimicrobial stewardship: what we all just need to know. Eur Urol Focus 2019; 5:46–49.
Ahmed R, Bashir A, Brown JEP, et al. The drugs don’t work: evaluation of educational theatre to gauge and influence public opinion on antimicrobial resistance. J Hosp Infect 2020; 104:193–197.
Edwards LJ. What are you having for dinner tonight? AMS: a stock feed miller's perspective. Aust Vet J 2019; 97:295–297.
Morris S, Cerceo E. Trends, epidemiology, and management of multi-drug resistant gram-negative bacterial infections in the hospitalized setting. Antibiotics (Basel) 2020; 9:196.
Yaacoub SG, Koyess V, Lahoud N, et al. Antibiotic prescribing for acute uncomplicated cystitis in Lebanese community pharmacies using a simulated patient. Pharm Pract (Granada) 2019; 17:1604.
Kiros T, Asrat D, Ayenew Z, Tsige E. Bacterial urinary tract infection among adult renal transplant recipients at St. Paul's hospital millennium medical college, Addis Ababa, Ethiopia. BMC Nephrol 2019; 20:289.
Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis 2019; 69: (Suppl 7): S565–S575.
Wang Y, Zhang Q, Jin Y, et al. Epidemiology and antimicrobial susceptibility profiles of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli in China. Braz J Microbiol 2019; 50:669–675.
Alsubaie SS, Barry MA. Current status of long-term antibiotic prophylaxis for urinary tract infections in children: an antibiotic stewardship challenge. Kidney Res Clin Pract 2019; 38:441–454.
DeMarsh M, Bookstaver PB, Gordon C, et al. Prediction of trimethoprim/sulfamethoxazole resistance in community-onset urinary tract infections. J Glob Antimicrob Resist 2019; 21:218–222.
Abbo LM, Hooton TM. Antimicrobial stewardship and urinary tract infections. Antibiotics (Basel) 2014; 3:174–192.
Li NY, Poh GQ, Teng GCW, et al. A prediction tool for the presence of ceftriaxone-resistant uropathogens upon hospital admission. Antibiotics (Basel) 2020; 9:316.
Onanuga A, Mahindroo J, Singh S, Taneja N. Phenotypic and molecular characterization of antimicrobial resistant Escherichia coli from urinary tract infections in Port-Harcourt, Nigeria. Pan Afr Med J 2019; 34:144.
Kim B, Myung R, Lee MJ, et al. Trend of antibiotics usage for acute pyelonephritis in Korea based on national health insurance data. BMC Infect Dis 2019; 19:554.
Gupta V, Ye G, Olesky M, et al. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States. BMC Infect Dis 2019; 19:742.
Tüzün T, Sayin Kutlu S, Kutlu M, Kaleli İ. Risk factors for community-onset urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Turk J Med Sci 2019; 49:1206–1211.
Vazouras K, Velali K, Tassiou I, et al. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections. J Glob Antimicrob Resist 2020; 20:4–10.
Jansåker F, Thønnings S, Hertz FB, et al. Three versus five days of pivmecillinam for community-acquired uncomplicated lower urinary tract infection: a randomised, double-blind, placebo-controlled superiority trial. EClinicalMedicine 2019; 12:62–69.
Bonkat G, Bartoletti R, Bruere F, et al. Guidelines on urological infections. Eur Urology 2020.
Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: a focus on side chains and β-lactam cross-reactivity. Pharmacy (Basel) 2019; 7:103.
Muldaeva G, Beisenayeva A, Arystan L, et al. The point prevalence survey research of antibacterial drugs’ prescription for outpatient treatment of urinary system infections. Open Access Maced J Med Sci 2019; 7:2551–2555.
Benko R, Matuz M, Juhasz Z, et al. Treatment of cystitis by hungarian general practitioners: a prospective observational study. Front Pharmacol 2019; 10:1498.
Yu JY, McKenna VA, Dumyati GK, et al. Antibiotic prescribing in New York State Medicare Part B beneficiaries diagnosed with cystitis between 2016 and 2017. Open Forum Infect Dis 2020; 7:ofz544.
Guo RF, Nguyen DL, Park S, et al. Practitioner education and feedback to decrease ciprofloxacin prescriptions in patients with acute uncomplicated cystitis. Perm J 2020; 24: 18.036. doi:10.7812/TPP/18.036.
doi: 10.7812/TPP/18.036
Pujades-Rodriguez M, West RM, Wilcox MH, Sandoe J. Lower urinary tract infections: management, outcomes and risk factors for antibiotic re-prescription in primary care. EClinicalMedicine 2019; 14:23–31.
Al-Sayyed B, Le J, Al-Tabbaa MM, et al. Uncomplicated urinary tract infection in ambulatory primary care pediatrics: are we using antibiotics appropriately? J Pediatr Pharmacol Ther 2019; 24:39–44.
Kulchavenya E, Neymark A, Kapsargin F, et al. Acute uncomplicated cystitis: do we follow guidelines? Eur Urol Suppl 2019; 18:e49.
Grigoryan L, Nash S, Zoorob R, et al. Qualitative analysis of primary care provider prescribing decisions for urinary tract infections. Antibiotics (Basel) 2019; 8:84.
Hecker MT, Son AH, Murphy NN, et al. Impact of syndrome-specific antimicrobial stewardship interventions on use of and resistance to fluoroquinolones: an interrupted time series analysis. Am J Infect Control 2019; 47:869–875.
European Medicine Agency. Available at: https://www.ema.europa.eu/en/news/fluoroquinolone-quinolone-antibiotics-prac-recommends-new-restrictions-use-following-review. [Accessed 25 August, 2020].
Cowart K, Worley M, Rouby NE, Sando K. Evaluation of FDA boxed warning on prescribing patterns of fluoroquinolones for uncomplicated urinary tract infections. Ann Pharmacother 2019; 53:1192–1199.
Kulchavenya E, Kholtobin D, Shevchenko S. Challenges in urogenital tuberculosis. World J Urol 2020; 38:89–94.
Kulchavenya EV, Yasuda M, Grabe M. Bjerklund Johansen TE, Wagenlehner FME, Matsumoto T, Cho YH, Krieger JN, Shoskes D, Naber KG. Epidemiology, classification, clinical features, and diagnostics of urogenital tuberculosis. Version: 2009-05-28. German Medical Science GMS Publishing House, Urogenital infections and inflammations. Berlin:2017.
Saran S, Rao NS, Azim A. New and promising antibacterials: can this promise be sustained? J Anaesthesiol Clin Pharmacol 2020; 36:13–19.
Provenzani A, Hospodar AR, Meyer AL, et al. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. Int J Clin Pharm 2020; 10.1007/s11096-020-01089-y. doi:10.1007/s11096-020-01089-y.
doi: 10.1007/s11096-020-01089-y.
doi: 10.1007/s11096-020-01089-y
Overcash JS, Tiffany CA, Scangarella-Oman NE, et al. Phase 2a pharmacokinetic, safety, and exploratory efficacy evaluation of oral gepotidacin (GSK2140944) in female participants with uncomplicated urinary tract infection (acute uncomplicated cystitis). Antimicrob Agents Chemother 2020; 64:e00199–e00120.
Vickers RJ, Bassetti M, Clancy CJ, et al. Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiol 2019; 14:1331–1341.
Garretto A, Miller-Ensminger T, Wolfe AJ, Putonti C. Bacteriophages of the lower urinary tract. Nat Rev Urol 2019; 16:422–432.
Vahlensieck W, Lorenz H, Schumacher-Stimpfl A, et al. Effect of a herbal therapy on clinical symptoms of acute lower uncomplicated urinary tract infections in women: secondary analysis from a randomized controlled trial. Antibiotics (Basel) 2019; 8:256.
Kulchavenya E. Acute uncomplicated cystitis: is antibiotic unavoidable? Ther Adv Urol 2018; 10:257–262.
Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A WHO practical toolkit. 2019. Available at: file:///C:/Users/1/Favorites/Downloads/9789241515481-eng.pdf. ISBN 978-92-4-151548-1. Association of Urology. Available at: https://uroweb.org/wp-content/uploads/. [Accessed 25 August, 2020].
Palavecino EL, Williamson JC, Ohl CA. Collaborative antimicrobial stewardship: working with microbiology. Infect Dis Clin North Am 2020; 34:51–65.
Sadyrbaeva-Dolgova S, Aznarte-Padial P, Jimenez-Morales A, et al. Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program. J Infect Public Health 2020; 13:558–563.
Knight J, Michal J, Milliken S, Swindler J. Effects of a remote antimicrobial stewardship program on antimicrobial use in a regional hospital system. Pharmacy (Basel) 2020; 8:41.
Maraolo AE, Ong DSY, Cimen C, et al. ESGAP-EUCIC-TAE Working Group on AMS/IPC mapping in Europe. Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey. Eur J Clin Microbiol Infect Dis 2019; 38:2061–2068.
Gebretekle GB, Haile Mariam D, Abebe Taye W, et al. Half of prescribed antibiotics are not needed: a pharmacist-led antimicrobial stewardship intervention and clinical outcomes in a referral hospital in Ethiopia. Front Public Health 2020; 8:109.
Kusama Y, Ishikane M, Tanaka C, et al. Regional variation of antimicrobial use in japan from 2013-2016, as estimated by the sales data. Jpn J Infect Dis 2019; 72:326–329.
Hughes SJ, Moore LS. Antimicrobial stewardship. Br J Hosp Med (Lond) 2019; 80:C42–C45.
Al-Hasan MN, Winders HR, Bookstaver PB, Justo JA. Direct measurement of performance: a new era in antimicrobial stewardship. Antibiotics (Basel) 2019; 8:127.
Uda A, Shigemura K, Kitagawa K, et al. How does antimicrobial stewardship affect inappropriate antibiotic therapy in urological patients? Antibiotics (Basel) 2020; 9:63.
Esteve-Palau E, Grau S, Herrera S, et al. Impact of an antimicrobial stewardship program on urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Rev Esp Quimioter 2018; 31:110–117.
Alias AM, Shahruniza AS, Sulaiman H. Stewardship opportunities in the treatment of urinary tract infection using oral fosfomycin. Med J Malaysia 2019; 74:456–458.
Song Y, Han Z, Song K, Zhen T. Antibiotic consumption trends in China: evidence from six-year surveillance sales records in Shandong Province. Front Pharmacol 2020; 11:491.
Zequinao T, Gasparetto J, Oliveira DDS, et al. A broad-spectrum beta-lactam-sparing stewardship program in a middle-income country public hospital: antibiotic use and expenditure outcomes and antimicrobial susceptibility profiles. Braz J Infect Dis 2020; 24:221–230.
Kpokiri EE, Taylor DG, Smith FJ. Development of antimicrobial stewardship programmes in low and middle-income countries: a mixed-methods study in Nigerian hospitals. Antibiotics (Basel) 2020; 9:204.
Dickstein Y, Temkin E, Ben-David D, et al. Antimicrobial use trends, Israel, 2012 to 2017. Euro Surveill 2019; 24:1900022.
Choi JK, Yoo JH. Increasing antimicrobial resistance of Escherichia coli makes antimicrobial stewardship more important. J Korean Med Sci 2019; 34:e236.
Akazawa T, Kusama Y, Fukuda H, et al. Eight-year experience of antimicrobial stewardship program and the trend of carbapenem use at a tertiary acute-care hospital in Japan-the impact of postprescription review and feedback. Open Forum Infect Dis 2019; 6:ofz389.
Choe HS, Lee SJu, Cho YH, et al. GPIU Asian Investigators. Aspects of urinary tract infections and antimicrobial resistance in hospitalized urology patients in Asia: 10-year results of the global prevalence study of infections in urology (GPIU). J Infect Chemother 2018; 24:278–283.